The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; et al. (Profiled Author: Nancy Davidson)
Division of Hematology-Oncology, Princess Margaret Hospital, Toronto, ON, Canada. firstname.lastname@example.org
The New England journal of medicine 2003;349(19):1793-802.
BACKGROUND: In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy--but not tamoxifen therapy of longer duration--prolongs disease-free and overall survival. The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy. METHODS: We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy. The primary end point was disease-free survival. RESULTS: A total of 5187 women were enrolled (median follow-up, 2.4 years). At the first interim analysis, there were 207 local or metastatic recurrences of breast cancer or new primary cancers in the contralateral breast--75 in the letrozole group and 132 in the placebo group--with estimated four-year disease-free survival rates of 93 percent and 87 percent, respectively, in the two groups (P< or =0.001 for the comparison of disease-free survival). A total of 42 women in the placebo group and 31 women in the letrozole group died (P=0.25 for the comparison of overall survival). Low-grade hot flashes, arthritis, arthralgia, and myalgia were more frequent in the letrozole group, but vaginal bleeding was less frequent. There were new diagnoses of osteoporosis in 5.8 percent of the women in the letrozole group and 4.5 percent of the women in the placebo group (P=0.07); the rates of fracture were similar. After the first interim analysis, the independent data and safety monitoring committee recommended termination of the trial and prompt communication of the results to the participants. CONCLUSIONS: As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
J N Ingle; D Tu; J L Pater; H B Muss; S Martino; N J Robert; M J Piccart; M Castiglione; L E Shepherd; K I Pritchard; et al.Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(5):877-82.
James N Ingle; Dongsheng Tu; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; et al.Breast cancer research and treatment 2006;99(3):295-300.
Paul E Goss; James N Ingle; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1948-55.
Appears in this Publication
Author of this Publication